Recent Investment Analysts’ Ratings Updates for ArriVent BioPharma (AVBP)

ArriVent BioPharma (NASDAQ: AVBP) recently received a number of ratings updates from brokerages and research firms:

• 10/16/2026 – ArriVent BioPharma had its “buy” rating reaffirmed by BTIG Research. They now have a $29.00 price target on the stock.
• 10/15/2026 – ArriVent BioPharma had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/10/2026 – ArriVent BioPharma was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 10/8/2026 – ArriVent BioPharma had its price target lowered by HC Wainwright from $47.00 to $27.00. They now have a “buy” rating on the stock.
• 10/7/2026 – ArriVent BioPharma had its price target lowered by Guggenheim from $45.00 to $18.00. They now have a “buy” rating on the stock.
• 10/7/2026 – ArriVent BioPharma had its price target lowered by BTIG Research from $42.00 to $29.00. They now have a “buy” rating on the stock.
• 10/7/2026 – ArriVent BioPharma had its price target lowered by Citigroup Inc. from $40.00 to $20.00. They now have a “buy” rating on the stock.
• 10/7/2026 – ArriVent BioPharma had its price target lowered by JonesTrading from $45.00 to $22.00. They now have a “buy” rating on the stock.
• 10/6/2026 – ArriVent BioPharma had its price target lowered by Truist Financial Corporation from $45.00 to $18.00. They now have a “buy” rating on the stock.
• 10/6/2026 – ArriVent BioPharma was given a new $18.00 price target by Jefferies Financial Group Inc..
• 9/22/2026 – ArriVent BioPharma had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 8/17/2026 – ArriVent BioPharma had its price target raised by HC Wainwright from $44.00 to $47.00. They now have a “buy” rating on the stock.

ArriVent BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing precision medicines for patients with genetically defined cancers. The company seeks to identify promising therapies developed in other regions and advance them through clinical development and regulatory approval in the United States and other markets.

ArriVent’s lead product candidate is furmonertinib, an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor designed to target specific EGFR mutations in non-small cell lung cancer, including EGFR exon 20 insertion mutations.